Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer

• Egile Nagusiak: Huina Wu (Egilea), Lei Sun (Egilea), Rui Feng (Egilea), Huiyue Zhang (Egilea), Ke Tang (Egilea), Shuo Wang (Egilea), Jing Nie (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Rezvilutamide, a novel androgen-receptor inhibitor with limited blood-brain barrier penetration, exhibits significant antitumour activity against highvolume, metastatic, hormone-sensitive prostate cancer (mHSPC). In this study, we aimed to compare the cost-effectiveness of rezvilutamide...